Cybin (CYBN) News Today $11.14 +0.13 (+1.18%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cybin (OTCMKTS:CYBN) Stock Price Up 0.2% - Should You Buy?Cybin (OTCMKTS:CYBN) Shares Up 0.2% - Still a Buy?November 6, 2024 | marketbeat.comCybin announces grant of patent in support of CYB005 phenethylamines programOctober 25, 2024 | markets.businessinsider.comBright Minds rally ends as psychedelic stocks extend volatilityOctober 16, 2024 | msn.comCybin Expands Clinical Team to Support CYB003 Phase 3 ProgramOctober 1, 2024 | finance.yahoo.comChewy executive conducted insider trading over pet insurance partnership, SEC saysSeptember 27, 2024 | ca.finance.yahoo.comClock is ticking for US recession, return of Fed's QE, says black swan fundSeptember 27, 2024 | ca.finance.yahoo.comCybin to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comCybin Inc (R7E1.DU)August 30, 2024 | nz.finance.yahoo.comCybin Inc (R7E1.MU)August 30, 2024 | nz.finance.yahoo.comCybin (OTCMKTS:CYBN) Shares Down 0.2% Cybin (OTCMKTS:CYBN) Shares Down 0.2%August 28, 2024 | marketbeat.comBuy Rating Affirmed for Cybin Amid Advancements in Psychedelic Medicine and Strategic Regulatory ApproachesJuly 31, 2024 | markets.businessinsider.comCybin (OTCMKTS:CYBN) Trading Down 1.8%Cybin (OTCMKTS:CYBN) Shares Down 1.8%July 20, 2024 | marketbeat.comCybin (OTCMKTS:CYBN) Shares Down 2.7% Cybin (OTCMKTS:CYBN) Trading Down 2.7%June 28, 2024 | marketbeat.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesMay 6, 2024 | finance.yahoo.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesMay 6, 2024 | businesswire.comCybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistryApril 18, 2024 | businesswire.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive DisorderApril 16, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin (OTCMKTS:CYBN) Trading Down 5.3%Cybin (OTCMKTS:CYBN) Shares Down 5.3%March 29, 2024 | marketbeat.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 26, 2024 | investorplace.comCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 MillionMarch 19, 2024 | businesswire.comCybin to Present at Public Ventures Discovery Day on March 19th in DallasMarch 18, 2024 | businesswire.comCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety DisorderMarch 15, 2024 | businesswire.comCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy RatingMarch 14, 2024 | markets.businessinsider.comCybin to begin Phase 3 study for psychedelic drug mid-yearMarch 14, 2024 | msn.comBuy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA DesignationsMarch 14, 2024 | markets.businessinsider.comCybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program DesignMarch 14, 2024 | businesswire.comCybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003March 13, 2024 | markets.businessinsider.comCybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive DisorderMarch 13, 2024 | businesswire.comCybin to Host Conference Call and Webcast to Provide Program Update for CYB003March 12, 2024 | businesswire.com3 High-Potential Penny Stocks to Turn $1000 into $1 millionMarch 10, 2024 | investorplace.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | businesswire.comCybin Inc.February 16, 2024 | thestreet.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 14, 2024 | finance.yahoo.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 14, 2024 | businesswire.comCybin (OTCMKTS:CYBN) Trading Up 10.8%Cybin (OTCMKTS:CYBN) Stock Price Up 10.8%February 13, 2024 | marketbeat.comCybin Announces Grant of Two Additional Patents in Japan in Support of its DMT ProgramFebruary 7, 2024 | finance.yahoo.comFDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized AnxietyJanuary 23, 2024 | msn.comCybin gets FDA clearance for Phase 2a study of psychedelic drugJanuary 23, 2024 | msn.comCybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety DisorderJanuary 23, 2024 | finance.yahoo.comBuy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic ValuationJanuary 5, 2024 | markets.businessinsider.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog ProgramDecember 6, 2023 | finance.yahoo.comCybin Reports Positive Data From Phase 2 CYB003 In Major Depressive DisorderNovember 30, 2023 | markets.businessinsider.comCybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg DosesNovember 30, 2023 | finance.yahoo.comCybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York CityNovember 20, 2023 | finance.yahoo.comCybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 GoalsNovember 15, 2023 | msn.comThinking about buying stock in Tesla Inc, Chevron, Theseus Pharmaceuticals, Cybin Inc, or NXU Inc.?November 15, 2023 | benzinga.comCybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding DealNovember 10, 2023 | benzinga.comCybin Prices Offering Of About 66.67 Mln Units At $0.45/unitNovember 10, 2023 | markets.businessinsider.com Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! CYBN Media Mentions By Week CYBN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼-0.640.45▲Average Medical News Sentiment CYBN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼00▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvation Bio News Today 89bio News Today Tyra Biosciences News Today Rapport Therapeutics News Today Relay Therapeutics News Today Evolus News Today Pliant Therapeutics News Today Cronos Group News Today Prothena News Today Replimune Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYBN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts